[PDF][PDF] Discriminating gender on Twitter
JD Burger, J Henderson, G Kim… - Proceedings of the 2011 …, 2011 - aclanthology.org
Accurate prediction of demographic attributes from social media and other informal online
content is valuable for marketing, personalization, and legal investigation. This paper …
content is valuable for marketing, personalization, and legal investigation. This paper …
[PDF][PDF] Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer
PA Philip, MR Mahoney, C Allmer, J Thomas, HC Pitot… - J Clin Oncol, 2005 - academia.edu
Purpose Epidermal growth factor receptor/human epidermal growth factor receptor 1
(EGFR/HER1) and ligand expression is frequently seen in hepatocellular cancers (HCCs) …
(EGFR/HER1) and ligand expression is frequently seen in hepatocellular cancers (HCCs) …
Real-world comparative effectiveness of nab-paclitaxel plus gemcitabine versus FOLFIRINOX in advanced pancreatic cancer: a systematic review
EG Chiorean, WY Cheung… - … in medical oncology, 2019 - journals.sagepub.com
Background: No clinical trial has directly compared nab-paclitaxel/gemcitabine (nab-P/G)
with FOLFIRINOX (fluorouracil/leucovorin/oxaliplatin/irinotecan) in metastatic or advanced …
with FOLFIRINOX (fluorouracil/leucovorin/oxaliplatin/irinotecan) in metastatic or advanced …
[PDF][PDF] Prognostic and predictive roles of high-degree microsatellite instability in colon cancer: a National Cancer Institute–National Surgical Adjuvant Breast and …
GP Kim, LH Colangelo, HS Wieand, S Paik… - Journal of clinical …, 2007 - researchgate.net
Prognostic and Predictive Roles of High-Degree Microsatellite Instability in Colon Cancer: A
National Cancer Institute–Nationa Page 1 Prognostic and Predictive Roles of High-Degree …
National Cancer Institute–Nationa Page 1 Prognostic and Predictive Roles of High-Degree …
Phase II study of erlotinib in patients with advanced biliary cancer
PA Philip, MR Mahoney, C Allmer, J Thomas… - Journal of Clinical …, 2006 - ascopubs.org
Purpose Epidermal growth factor receptor/human epidermal growth factor receptor 1 and
ligand expression is common in biliary cancers (BILI) and may be associated with worse …
ligand expression is common in biliary cancers (BILI) and may be associated with worse …
Prognostic Value of Thymidylate Synthase, Ki-67, and p53 in Patients With Dukes' B and C Colon Cancer: A National Cancer Institute–National Surgical Adjuvant …
CJ Allegra, S Paik, LH Colangelo, AL Parr… - Journal of Clinical …, 2003 - ascopubs.org
Purpose: To define the value of thymidylate synthase (TS), Ki-67, and p53 as prognostic
markers in patients with stage II and III colon carcinoma. Patients and Methods: We …
markers in patients with stage II and III colon carcinoma. Patients and Methods: We …
[HTML][HTML] Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a phase II …
SJ Lubner, MR Mahoney, JL Kolesar… - Journal of Clinical …, 2010 - ncbi.nlm.nih.gov
Purpose Biliary cancers overexpress epidermal growth factor receptor (EGFR), and
angiogenesis has been correlated with poor outcome. Erlotinib, an EGFR tyrosine kinase …
angiogenesis has been correlated with poor outcome. Erlotinib, an EGFR tyrosine kinase …
Cold spray deposition of nanocrystalline aluminum alloys
Aluminum 5083 powder was mechanically milled under liquid nitrogen to achieve a
nanocrystalline grain size in the range of 20 to 30 nm. The powder was subsequently …
nanocrystalline grain size in the range of 20 to 30 nm. The powder was subsequently …
Adjuvant radiotherapy and chemotherapy for pancreatic carcinoma: the Mayo Clinic experience (1975-2005)
MM Corsini, RC Miller, MG Haddock… - Journal of Clinical …, 2008 - ascopubs.org
Purpose To determine prognostic factors and impact of adjuvant chemotherapy (CT) and
radiotherapy (RT) on overall survival (OS) after resection of pancreatic adenocarcinoma …
radiotherapy (RT) on overall survival (OS) after resection of pancreatic adenocarcinoma …
Targeting colorectal cancer with human anti-EGFR monoclonocal antibodies: focus on panitumumab
GP Kim, A Grothey - Biologics: Targets and Therapy, 2008 - Taylor & Francis
The human anti-epidermal growth factor receptor (EGFR) monoclonal antibody,
panitumumab, represents a significant advance in the treatment of colorectal cancer. The …
panitumumab, represents a significant advance in the treatment of colorectal cancer. The …